Is it cannabis-induced psychosis or bipolar disorder?

Patient details have been changed and combined where necessary to protect privacy.

This week, I evaluated two young people who had recently been hospitalized after developing psychosis in the setting of heavy cannabis use. Both had been discharged with serious psychiatric diagnoses and multiple medications. Both families were frightened. And in both cases, the central clinical question remained insufficiently answered: Was this the onset of a primary psychiatric disorder, or was it cannabis-induced psychosis? The answer could shape a young person’s treatment, prognosis, identity, educational plans, employment opportunities, insurance record, and willingness to seek psychiatric care for years to come.

One of these patients was an eighteen-year-old young woman who had recently graduated from high school. She was an only child and had recently lost her fifteen-year-old Labrador retriever, the dog she had grown up with. He had been a constant companion and, in many ways, felt more like a sibling than a pet. She was grieving that loss while preparing for college and facing significant anxiety and uncertainty about the future. During this period, she began using a high-potency THC extract daily.

Then she stopped sleeping.

As the sleep deprivation worsened, her thinking changed. She became preoccupied with religious revelations, was seeing signs and codes in things, and “Now everything made sense.” Her speech was frantic. She was pacing, moving furniture in the house, and was irritable if anyone tried to stop her or slow her down. Her family could no longer follow her thought process or safely manage her at home. She was hospitalized and diagnosed with bipolar I disorder.

The presentation certainly resembled mania with psychotic features. She had decreased sleep, altered behavior, unusual beliefs, and disorganized thinking. Acute cannabis-induced psychosis, however, can look nearly identical.

The diagnosis cannot rest only on how a patient appears at the height of a crisis. Clinicians must also examine what happened before the episode, which substances were used, the potency and frequency of exposure, the degree of sleep deprivation, whether symptoms continued after intoxication resolved, and what emerged during sustained abstinence.

Today’s cannabis is not the cannabis many adults remember

Public perception has not kept pace with cannabis potency. The average THC concentration in cannabis plant material has increased substantially over the past several decades. Concentrates, extracts, vape cartridges, wax, shatter, and dabs may contain far higher levels of THC than traditional cannabis flower.

The route of administration also changes the risk. Concentrated products can deliver a large dose rapidly. Edibles can produce delayed and unpredictable effects, leading users to consume more before the initial dose has fully taken effect.

For many people, cannabis does not cause psychosis. Risk, however, is not evenly distributed. Age, genetics, previous psychiatric symptoms, frequency of use, THC potency, sleep deprivation, trauma, co-occurring substance use, and personal or family psychiatric history may all influence vulnerability.

THC can produce paranoia, suspiciousness, perceptual disturbances, delusional thinking, and disorganization even in people without a previously diagnosed psychotic disorder. Higher levels of cannabis exposure are associated with greater psychosis risk, supporting a dose-response relationship.

Cannabis-induced psychosis is not a benign diagnosis

Cannabis-induced psychosis is a serious psychiatric event that may require hospitalization, antipsychotic treatment, intensive family involvement, and close follow-up. It is also associated with a substantial risk of later psychiatric illness.

A Danish registry study followed 6,788 people diagnosed with substance-induced psychosis. Overall, 32.2 percent later developed schizophrenia-spectrum or bipolar disorder. Among those with cannabis-induced psychosis, 47.4 percent later received one of those diagnoses.

A large Ontario cohort found that approximately 26 percent of people who presented to an emergency department with cannabis-induced psychosis were diagnosed with a schizophrenia-spectrum disorder within three years. The corresponding rate after alcohol-induced psychosis was approximately 8.9 percent. Among the substances studied, cannabis-induced psychosis carried the highest risk of later transition to schizophrenia-spectrum illness.

These statistics should not be used to tell every patient that they are destined to develop schizophrenia or bipolar disorder. They should be used to justify careful follow-up, sustained abstinence, and an honest discussion about future risk.

Two common clinical errors should be avoided. The first is assigning a lifelong primary psychiatric diagnosis too quickly. The second is dismissing the episode as a temporary bad reaction once the acute symptoms improve. Both approaches can harm the patient.

Diagnostic humility is not indecision

In acute psychiatric settings, clinicians often have incomplete information. The patient may be frightened, disorganized, sleep-deprived, intoxicated, withdrawing, heavily medicated, or unable to provide a reliable history. Family members may not know exactly what products were used, how potent they were, or how frequently they were consumed.

A urine drug screen may confirm cannabis exposure, but it cannot establish timing, dose, potency, or whether cannabis caused the episode. The immediate responsibility of the hospital is stabilization. That may require antipsychotic medication, mood stabilization, restoration of sleep, reduction of agitation, and protection from harm.

The diagnostic process should continue after discharge. A careful follow-up assessment should examine:

• The timing of cannabis use relative to symptom onset
• The type of product used
• THC concentration, frequency, and approximate dose
• Use of other substances, stimulants, supplements, or hormones
• The number of nights without adequate sleep
• Previous spontaneous episodes of mania, hypomania, or psychosis
• Baseline personality, cognition, and level of functioning
• Family history of bipolar disorder, schizophrenia, or psychotic illness
• Persistence of symptoms during sustained abstinence
• Recovery of insight, sleep, organization, cognition, and functioning

A patient who develops psychosis after escalating daily use of concentrated THC and several nights without sleep presents a different diagnostic picture from someone with recurrent manic or psychotic episodes that occur independently of substances. The long-term prognosis may still be uncertain. The clinical formulation should reflect that uncertainty rather than conceal it.

The diagnosis becomes part of the patient’s identity

Psychiatric diagnoses can provide clarity, access to treatment, and relief. They can also become psychologically heavy, particularly when assigned during a first hospitalization in adolescence or early adulthood.

A diagnosis of bipolar I disorder or a schizophrenia-spectrum illness may change how the patient interprets every future emotion, sleepless night, creative idea, or stressful period. Families may become hypervigilant. Later clinicians may interpret new symptoms through the lens of the original diagnosis. Medications started during an emergency may continue for years without a structured reassessment of whether the diagnosis still fits.

The opposite error can be equally dangerous. If the entire episode is attributed to cannabis without adequate follow-up, the patient may stop medication abruptly, return to THC, ignore residual symptoms, or avoid psychiatric care because the event is framed as a one-time reaction.

After a first episode, the most accurate diagnosis may be provisional. The patient may have experienced cannabis-induced psychosis. Cannabis and sleep deprivation may also have exposed an underlying vulnerability to bipolar or schizophrenia-spectrum illness. Only abstinence, collateral history, ongoing observation, and longitudinal follow-up can clarify the course.

What clinicians should tell patients and families

The safest recommendation after cannabis-associated psychosis is complete avoidance of THC. This includes cannabis flower, concentrates, vape cartridges, delta-8 THC, delta-9 THC, high-dose edibles, and other intoxicating cannabinoid products. “Cutting back” is not an adequate relapse-prevention strategy after hospitalization for psychosis.

Sleep should also be treated as a central clinical variable. Several nights of severely reduced sleep can intensify paranoia, perceptual disturbances, emotional dysregulation, impulsivity, and disorganized thinking.

Families should receive clear instructions about early warning signs, including:

• Reduced need for sleep
• Increasing suspiciousness
• Religious or grandiose preoccupation
• Disorganized speech or behavior
• Social withdrawal
• Agitation
• Declining insight
• Renewed cannabis use

They should also know when to contact the outpatient clinician, when to seek urgent evaluation, and when emergency services are needed. Medication decisions should be individualized and gradual. Improvement after an antipsychotic does not prove a primary psychotic disorder. Antipsychotics also treat substance-induced psychosis. Rapid improvement after cannabis cessation does not eliminate future risk.

Follow-up should assess more than whether manic symptoms, paranoia, hallucinations, or other symptoms of psychosis have stopped. Clinicians should monitor sleep, cognition, motivation, anxiety, depression, social functioning, school or work performance, insight, substance cravings, medication adverse effects, and subtle recurrence of psychotic symptoms.

We need to ask better questions

Cannabis legalization has understandably changed public attitudes. Legal does not mean harmless. Natural does not mean pharmacologically safe.

When a young person arrives at an emergency department with acute psychosis, clinicians should ask more than whether the presentation resembles bipolar disorder or schizophrenia. We should also ask:

• What cannabis product was used?
• How potent was it?
• How frequently was it used?
• When did the patient last sleep normally?
• Did symptoms begin before or after THC use escalated?
• Has anything similar happened during a sustained period of abstinence?
• What symptoms remain after intoxication, sleep deprivation, and the acute crisis have resolved?

The young woman I evaluated required treatment for the severity of what happened. She also deserved diagnostic precision. She may ultimately meet criteria for bipolar I disorder. She may not. Her episode may prove to have been cannabis-induced psychosis, or cannabis may have exposed a vulnerability that will become clearer over time.

The appropriate response is neither false reassurance nor premature certainty. It is stabilization, complete THC abstinence, close psychiatric follow-up, careful reassessment, and enough humility to let the longitudinal course guide the diagnosis.

A psychiatric label can follow a young person for life. We should make sure it fits.

This essay is cited in the KevinMD record on mental health.

Carrie Friedman is a dual board-certified psychiatric and family nurse practitioner and the founder of Brain Garden Psychiatry in California. She integrates evidence-based psychopharmacology with functional and integrative psychiatry, emphasizing root-cause approaches that connect neuro-nutrition and gut–brain science, metabolic psychiatry, immunology, endocrinology, and mind–body lifestyle medicine. Carrie’s clinical focus bridges conventional psychiatry with holistic strategies to support mental health through nutrition, physiology, and sustainable lifestyle interventions. Her professional writing explores topics such as functional medicine, autism, provider well-being, and medical ethics.